Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 50(3); 2018 > Article
Original Article Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, MD, PhD1,2,3, Keun-Wook Lee, MD, PhD1,4, Do-Youn Oh, MD, PhD1,2,3, Jong-Seok Lee, MD, PhD1,4, Seock-Ah Im, MD, PhD1,2,3, Dong-Wan Kim, MD, PhD1,2,3, Sae-Won Han, MD, PhD1,2,3, Yu Jung Kim, MD, PhD1,4, Tae-You Kim, MD, PhD1,2,3, Jee Hyun Kim, MD, PhD1,4, Hyesun Han, MS5, Woo Ho Kim, MD, PhD2,6, Yung-Jue Bang, MD, PhD1,2,3,
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(3):835-842.
DOI: https://doi.org/10.4143/crt.2017.303
Published online: August 29, 2017

1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

2Seoul National University Cancer Research Institute, Seoul, Korea

3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

4Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

5Hanmi Pharm. Co., Ltd., Seoul, Korea

6Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

Correspondence: Yung-Jue Bang, MD, PhD Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: 82-2-2072-2390 Fax: 82-2-764-2199 E-mail: bangyj@snu.ac.kr
*Data from these studies were presented in part at the annual meetings of the American Society of Clinical Oncology 2012 and 2013, Chicago, IL, USA; and 15th World Conference on Lung Cancer 2013, Sydney, Australia.
• Received: June 22, 2017   • Accepted: August 18, 2017

Copyright © 2018 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 13,811 Views
  • 689 Download
  • 61 Web of Science
  • 59 Crossref
  • 65 Scopus
prev next
  • Purpose
    Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of epidermal growth factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4 and EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity against advanced solid tumors.
  • Materials and Methods
    Standard 3+3 dose escalation scheme using two different dosing schedules were studied: once daily, 14-day on, and 7-day off (intermittent schedule); and once daily continuous dosing with food effect. Additional patients were enrolled in an expansion cohort.
  • Results
    A total of 75 patients were enrolled in the two studies. The most common drug-related treatment-emergent adverse eventswere diarrhea,rash, stomatitis, pruritus, and anorexia. Dose-limiting toxicities were grade 3 diarrhea in the intermittent schedule and grade 3 anorexia and diarrhea in the continuous dosing schedule. The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule. Eight (16%) and 24 (47%) of 51 evaluable patients in the intermittent schedule achieved partial response (PR) and stable disease (SD), respectively. Four (21%) and six (32%) of 19 evaluable patients in continuous dosing schedule achieved PR and SD, respectively. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer).
  • Conclusion
    Poziotinib was safe and well tolerated in patients with advanced solid tumors. It showed an encouraging activity against EGFR-mutant and HER2-amplified cancers.
The ErbB family of receptors is mutated or overexpressed in many solid tumors and aberrantly activated ErbB receptor signals have been associated with poor prognosis [1]. Among ErbB receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) have been implicated as important therapeutic targets for lung, breast, and gastric cancers. The first-generation EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib reversibly inhibit EGFR tyrosine kinase by competing with adenosine triphosphate [1]. These have shown clinical benefits for EGFR-mutant non-small cell lung cancer (NSCLC) with median progression-free survivals of 9 to 11 months; however, acquired resistance to these TKIs is inevitable [2]. Due to limited clinical success of first-generation EGFR TKI, second-generation and irreversible EGFR TKIs have been developed for targeting EGFR, HER2, and ErbB4 such as dacomitinib and afatinib [3]. These second-generation EGFR TKIs have shown favorable survival outcomes in lung adenocarcinoma with activating EGFR mutations [4-6].
Poziotinib (HM781-36B) is an irreversible pan-HER TKI, which targets EGFR, HER2, and ErbB4. Poziotinib shows good in vitro activities in EGFR or HER2 expressing various cancer cell lines including EGFR TKI–resistant lung cancer cells. Poziotinib effectively inhibited ErbB family kinases (IC50, 3.2, 2.2, 5.3, and 23.5 nM against EGFRwild-type, EGFRT790M/L858R, HER2, and HER4, respectively) [7]. In addition, HER2-amplified gastric cancer cells and breast cancer cells were sensitive to poziotinib alone (IC50, 1-4 nM and 1-9 nM, respectively) or poziotinib in combination with various chemotherapeutic agents [8,9].
Here, we conducted the first-in-human phase I studies of poziotinib to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity in patients with advanced solid tumors.
1. Patients
Eligible patients were ≥ 19 years with histologically or cytologically confirmed advanced solid tumor, Eastern Cooperative Oncology Group performance status ≤ 2; with previous chemotherapy, a life expectancy greater than 12 weeks; and adequate bone marrow (absolute neutrophil count ≥ 1,500/mm3, platelet ≥ 100,000/mm3, and hemoglobin ≥ 9.0 g/dL), renal (serum creatinine ≤ 1.5 mg/dL) and hepatic (serum transaminases ≤ 3× upper limit of normal and total bilirubin ≤ 2 mg/dL) functions. Patients who had undergone radiation therapy or surgery within 4 weeks prior to study were excluded. Patients were excluded if they had uncontrolled infection, ileus, metastasis to central nervous system, class III or IV heart failure or left ventricular ejection fraction < 40%, gastrointestinal malabsorption or difficulty in taking oral medication, or taken other investigational products within 30 days before screening.
2. Study design and treatment
We conducted two phase I, open label studies to determine the MTD for two different dosing schedules. In NCT0145571 (study A), poziotinib tablet was administered with water once daily on an intermittent basis (14-day on and 7-day off) schedule at multiple dose levels (0.5, 1, 2, 4, 8, 12, 16, 20, 24, and 32 mg) (n=55, study A), and in NCT01455584 (study B), poziotinib was given once daily in a continuous dosing fashion, at dose levels of 12, 18, and 24 mg and 16 mg with food in the fasting or fed state by period in a cross-over design (n=20, study B). In the dose escalation part for both studies, cohorts of three to six patients were treated at increasing doses of poziotinib to determine the MTD. A traditional 3+3 dose-escalation design was used with MTD defined as the dose where dose-limiting toxicities (DLTs) observed in one or more out of six patients in the first cycle. Once the MTD was identified, 12 patients were enrolled in the expansion part (study A, only). Food effect was conducted based on a 2×2 cross-over design (fasting-fed sequence versus fed-fasting sequence after randomization) once the recommended dose (RD) was determined (study B, only).
3. Pharmacokinetic analyses
In study A, serial blood and urine samples were collected on day 1 for up to 24 hours (just before administration, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours after dosing) and day 14 of cycle 1 up to 48 hours (just before administration, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours after dosing) (n=52). To assess the food effect on pharmacokinetic (PK) of poziotinib in study B, eigh additional patients were enrolled, and blood samples were taken on day 1 and day 8 up to 24 hours (just before administration, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after dosing) on fasting or fed condition (n=8). Plasma samples were analyzed for poziotinib concentration at BioInfra Co., Ltd. (Suwon, Korea). The analytes were extracted from heparinized human plasma. The analytes were then separated and detected by validated ultra-performance liquid chromatography with tandem mass spectrometry [10]. Noncompartmental analysis for plasma concentration was performed using Phoenix WinNonlin Software ver. 6.3 (Pharsight, Mountain View, CA).
4. Efficacy and safety analyses
Adverse events (AEs) and treatment-emergent AEs (TEAEs) were evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events ver. 3.0. DLTs were defined as grade ≥ 3 non-hematologic toxicities (except for alopecia), grade ≥ 3 diarrhea, nausea and vomiting despite maximal anti-diarrheal, anti-emetics medication, grade 4 neutropenia sustained for 7 days or more or febrile neutropenia, grade ≥ 3 neutropenic infection accompanying grade 4 neutropenia or grade 4 thrombocytopenia. Treatment response to poziotinib was evaluated every two cycles based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST) ver. 1.0 [11]. Progression-free survival (PFS) was measured as the interval between poziotinib first dose administration and the date when disease progression by RECIST ver. 1.0 or death was first documented.
5. Biomarker and molecular analyses
Plasma or tumor samples in the expansion cohort (n=12, study A) and in the continuous and food effect cohort (n=20, study B) were collected for EGFR mutation on exons 18-21, KRAS mutation on exon 2, BRAF mutation on exon 15, and PIK3CA mutation on exons 9 and 20 using a peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) method (PANAGENE, Inc., Daejeon, Korea) [12]. Plasma hepatocyte growth factor (HGF) concentration was determined using quantitative sandwich enzyme immunoassay technique (Seoul Clinical Laboratories Co., Ltd., Yongin, Korea). Plasma and tumor samples derived from patients (n=14, studies A and B) with partial response (PR) or stable disease (SD) ≥ 12 weeks were examined for EGFR (EGFR/CEP7 probe, Abbott Laboratories, Des Plaines, IL), HER2 (HER2/CEP7 probe, Abbott Laboratories), HER3 (HER3/CEN12 probe, ZytoVision GmbH, Bremerhaven, Germany), or HER4 (HER4/2q11 probe, ZytoVision GmbH) amplification and EGFR or HER2 mutation (PNA-mediated clamping PCR or direct sequencing).
6. Ethical statement
These studies were conducted in compliance with the Declaration of Helsinki and following the International Conference on Harmonization Good Clinical Practice Guidelines. In addition, these studies were approved by the Institutional Review Board of each participating center. Written informed consents were obtained.
1. Patients
A total of 75 patients were enrolled in both studies (55 in the intermittent schedule and 20 patients in the continuous dosing schedule, respectively). Study A included 43 patients in the dose escalation portion and 12 patients in the expansion cohort at the MTD. Study B included 12 patients in the dose escalation portion and eight patients in the food effect cohort. Nearly one-third of the patients (n=27) in both studies had a diagnosis of NSCLC and the majority of patients (65%) received fourth-line or above chemotherapeutic regimens (Table 1).
2. Safety profiles
All 75 patients were included in the safety analysis. Fifty-two patients (95%) in the intermittent schedule and 20 patients (100%) in the continuous schedule experienced at least one drug-related AE. The most common drug-related TEAEs were diarrhea, rash, stomatitis, pruritus, and anorexia (Table 2). DLTs in the intermittent dosing schedule were grade 3 diarrhea in five patients (one each at 12, 16, 24 mg levels, and two at 32 mg) in dose escalation part and grade 3 diarrhea in three patients, grade 3 nausea in one patient, and grade 3 mucosal inflammation in one patient in 24 mg expansion part (Table 3). DLTs in the continuous dosing schedule were grade 3 anorexia (one at 18 mg), grade 3 diarrhea with anorexia (one at 24 mg), and drug compliance as defined by actual dosage administered/dosage that should be administered ×100 < 80% due to grade 2 toxicities such as anorexia, rash, nausea, fatigue and diarrhea (one at 24 mg) (Table 3). The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule.
3. Efficacy
There were 51 evaluable patients by RECIST ver. 1.0 in the intermittent dosing schedule (study A) and out of those, eight patients (16%) achieved PR (breast cancer, n=4; NSCLC, n=2; and gastric and colorectal cancers, n=1, respectively) and 24 (47%) had SD (Fig. 1A). The disease control rate (DCR, PR+SD) was 63%. The median PFS was 12.0 weeks (95% confidence interval [CI], 7.4 to 16.5) for all patients and 13.4 weeks (95% CI, 11.5 to 18.9) in patients treated with at least 8 mg/day (n=39). All of the three patients (100%) receiving 8 mg/day developed a rash, a well-known AE related with inhibition of wild-type EGFR. Considering Ki-67–positive cells decreased after treatment with ≥ 8 mg poziotinib, the minimum effective dose for poziotinib was estimated to be 8 mg/day.
There were 19 evaluable patients in the continuous dosing schedule (study B). Four patients (21%) including two breast and one common bile duct cancers and one NSCLC achieved PR and six (32%) achieved SD; the DCR was 53% (Fig. 1B). The median PFS was 9.0 weeks (95% CI, 5.7 to 39.7). Among 27 NSCLC patients, 26 had received prior EGFR TKIs (first-generation EGFR TKIs, n=26; and second-generation EGFR TKIs, n=3). Three (11%) and 11 (41%) patients achieved PR and SD, respectively (Fig. 1C). The median PFS was 11.4 weeks (range, 5.6 to 17.4 weeks).
4. Pharmacokinetics
PK data for poziotinib was previously reported [10]. Briefly, dose-proportional pharmacokinetics profiles were observed in terms of Cmax and area under plasma concentration-time curve (AUC) in dose range of 0.5 to 24 mg on day 1. Absorption rate of poziotinib was moderate to high with a median Tmax between 0.6 and 4 hours and mean terminal half-lives ranged from 5.09 to 9.92 hours in day 1. PK parameters were similar between single (on day 1) and multiple oral doses (on day 14).
There was minimal difference in the geometric mean AUC values of poziotinib between dosing under fed conditions and dosing under fasting conditions. The geometric mean Cmax of poziotinib decreased approximately by 27% under fed conditions compared with fasting conditions. The median Tmax of poziotinib was delayed from 1.26 (0.95, 3.00) to 3.01 (1.00, 7.85) hours with food intake (S1 Table).
5. Molecular studies
Tissue (n=9) and plasma (n=12) samples in the expansion part of study A (intermittent dosing schedule) and plasma (n=9) samples in the continuous dosing schedule (study B) were collected for genetic studies. EGFR exon 19 deletion was observed in five NSCLC patients’ tissue samples, two of which harbored concomitant EGFRT790M mutation. Plasma or tumor samples showed EGFR exon 19 deletions (n=6), EGFRT790M mutation (n=5), EGFRL858R or EGFRL861Q mutation (n=2), and KRAS mutation (n=1). Molecular profiles, HGF concentrations and best response are described in S2 Table. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer) (S3 Table).
Poziotinib is an irreversible pan-HER TKI that has shown a manageable safety profile in our first-in-human studies, very similar to those seen with other TKIs. The MTDs were determined as 24 mg/day in the intermittent dosing schedule 2 (study A) and 18 mg/day in study B (continuous dosing) with a RD of 16 mg once daily. A linear increase in poziotinib exposure with increasing doses was observed in PK analyses. The best overall responses were 15.7% in study A and 21.1% in study B, respectively. In addition, encouraging efficacy was observed in EGFR-mutant NSCLC and HER2-amplified breast or stomach cancers. The most common AEs observed were diarrhea, skin rash, stomatitis, and pruritus and DLT was diarrhea, in line with other irreversible pan-HER TKIs [13,14].
To evaluate the PK profile, PK and plasma assessments were performed on days 1 and 14 of the cycle 1 from 52 of a total of 55 patients in study A. The exposure to poziotinib increased generally dose-proportionally at doses up to 24 mg/day (i.e., MTD) and these data indicate that human PK of poziotinib showed dose dependency on oral absorption. In addition, the PK parameters relevant to poziotinib exposure at steady state (on day 14) were similar to those obtained following a single dose (on day 1) suggesting no accumulation of poziotinib after multiple administrations. In terms of food effect, PK data showed delay in Tmax and decreased in Cmax of poziotinib with food, but there were no significant differences in the exposure (AUC). Therefore, the anticancer activity of poziotinib is not altered by food ingestion.
In the present studies, EGFR, HER2, KRAS, BRAF, PIK3CA mutations, EGFR and HER2 amplifications, as well as plasma HGF concentrations were analyzed in an exploratory manner. In terms of the best overall response by genetic status, one NSCLC patient with EGFR exon 19 deletion mutation achieved SD and two NSCLC patients with EGFR exon 19 deletion and T790M mutation showed SD and PR, respectively. Although two NSCLC patients progressed despite the presence of EGFR activating mutations, this might be due to unknownresistance mechanisms associated with EGFR TKIs, considering that the tumor sample was collected after previous treatment with EGFR TKIs. Taken together, after treatment with poziotinib, SD or PR was confirmed in three of six NSCLC patients with EGFR exon 19 deletion mutation or concomitant EGFR exon 19 deletion and T790M mutation. Poziotinib showed encouraging efficacy in EGFR-mutant NSCLC after failure of prior EGFR TKIs (PR, 12.5%) unlike other pan-HER inhibitors [13,14]. In addition, half of patients with clinical benefit (PR or SD ≥ 12 weeks) had HER2 amplification, mostly observed in patients with breast or stomach cancers. These results have led to the initiation of other poziotinib trials in various solid tumors, including EGFR-mutant lung adenocarcinoma as a first-line (NCT01819428) and as a second-line after failure to first-generation EGFR TKIs (NCT01718847), as well as in HER2-overexpressed breast and gastric cancers (NCT02418689, NCT02659514 and NCT01746771, respectively).
In conclusion, poziotinib is a promising irreversible pan-HER inhibitor against EGFR-mutant NSCLC as well as HER2-overexpressing breast and gastric cancers and was generally tolerated in heavily pre-treated cancer patients.
Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

Conflict of interest relevant to this article was not reported.

Fig. 1.
(A) Waterfall plot shows tumor size changes of target lesions in patients who received poziotinib once daily on a 14-day on and 7-day off schedule (n=46). (B) Waterfall plot shows tumor size changes of target lesions in patients treated with poziotinib once daily continuously (n=16). (C) Waterfall plot for non-small cell lung cancer (NSCLC) patients.
crt-2017-303f1.gif
Table 1.
Patient characteristics
Characteristic Intermittent dosing schedule (n=55) Continuous dosing schedule (n=20)
Sex
 Male 31 (56) 13 (65)
 Female 24 (44) 7 (35)
Age (yr) 55 (25-83) 55 (32-77)
ECOG PS
 0 30 (55) 8 (40)
 1 22 (40) 12 (60)
 2 2 (4) 0
 3 1 (2) 0
Cancer
 NSCLC 22 (40) 5 (25)
 Stomach 10 (18) 3 (15)
 Breast 8 (15) 2 (10)
 Colorectal 9 (16) 6 (30)
 Others 6 (11) 4 (20)
Prior regimen
 1-2 9 (16) 3 (15)
 3 9 (16) 5 (25)
 ≥ 4 37 (67) 12 (60)

Values are presented as number (%) or median (range). ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer.

Table 2.
Poziotinib-related TEAEs (≥ 10%)
TEAEs, preferred terms Intermittent dosing schedule (n=55)
Continuous dosing schedule (n=20)
Grade 1-4 ≥ Grade 3 Grade 1-4 ≥ Grade 3
Diarrhea 48 (87) 8 (15) 20 (100) 3 (15)
Rash 46 (84) 1 (2) 13 (65) -
Stomatitis 40 (73) - 16 (80) 1 (5)
Pruritus 33 (60) - 11 (55) 1 (5)
Decreased appetite 20 (36) 1 (2) 11 (55) 2 (10)
Acne 17 (31) - - -
Dermatitis acneiform 2 (4) - 6 (30) 2 (10)
Palmar-plantar erythrodysaesthesia syndrome 18 (33) - 3 (15) -
Rhinorrhea 14 (26) - 6 (30) -
Paronychia 13 (24) - 13 (65) -
Mucosal inflammation 13 (24) 1 (2) 6 (30) -
Nausea 11 (20) 1 (2) 4 (20) -
Vomiting 10 (18) 1 (2) 4 (20) -
Fatigue 8 (15) - 3 (15) -
Skin exfoliation 8 (15) - - -
Dry skin 6 (11) - 6 (30) 2 (10)
Weight decreased 6 (11) - - -

Values are presented as number (%). TEAEs, treatment-emergent adverse events.

Table 3.
DLTs in dose escalation and extension phases
Dose (mg) Intermittent dosing schedule
Continuous dosing schedule
No. of patients No. of DLTs DLT details No. of patients No. of DLTs DLT details
0.5 3 - - - - -
1 3 - - - - -
2 3 - - - - -
4 3 - - - - -
8 3 - - - - -
12 6 1 Diarrhea 3 - -
16 6 1 Diarrhea - - -
18 - - - 6 1 Decreased appetite
20 3 - - - - -
24 6 1 Diarrhea 3 1 Diarrhea
Drug compliance < 80%
32 7 2 Diarrhea - - -
24 Extension 12 5 3 Diarrhea, 1 nausea, 1 mucosal inflammation - - -

DLT, dose-limiting toxicity.

  • 1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54. ArticlePubMed
  • 2. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389–400. ArticlePubMedPMCPDF
  • 3. Dienstmann R, De Dosso S, Felip E, Tabernero J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol. 2012;6:15–26. ArticlePubMedPMC
  • 4. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–34. ArticlePubMed
  • 5. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–22. ArticlePubMed
  • 6. Janne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:1433–41. ArticlePubMed
  • 7. Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012;130:2445–54. ArticlePubMed
  • 8. Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011;302:155–65. ArticlePubMed
  • 9. Kim HJ, Kim HP, Yoon YK, Kim MS, Lee GS, Han SW, et al. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anticancer Drugs. 2012;23:288–97. ArticlePubMed
  • 10. Noh YH, Lim HS, Jung JA, Song TH, Bae KS. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2015;75:97–109. ArticlePubMed
  • 11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. ArticlePubMedPDF
  • 12. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer. 2012;75:321–5. ArticlePubMed
  • 13. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98:80–5. ArticlePubMedPMCPDF
  • 14. Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17:1131–9. ArticlePubMedPMC

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
      Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, Adrian Sacher, Paul Wheatley-Price, Stephanie Snow, Ming-Sound Tsao, Natasha B. Leighl, Ilidio Martins, Parneet Cheema, Geoffrey Liu, Quincy S. C. Chu
      Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
    • Cellular polarity pilots breast cancer progression and immunosuppression
      Jie Huang, Shufeng Luo, Juan Shen, Maya Lee, Rachel Chen, Shenglin Ma, Lun-Quan Sun, Jian Jian Li
      Oncogene.2025; 44(12): 783.     CrossRef
    • The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
      Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R. Del Bigio, Xin Xu, Amy Q. Wang, Darian Williams, Raul Calvo, Abhijeet Kapoor, Juan J. Marugan, Mark J. Henderson, Thomas Klonisch, Sabine Homb
      Cancer Research.2025; 85(8): 1514.     CrossRef
    • Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
      Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaki Shimoji, Masaoki Ito, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani, Tetsuya Mitsudomi
      Journal of Thoracic Oncology.2024; 19(1): 71.     CrossRef
    • Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
      Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky
      Breast Cancer Research and Treatment.2024; 205(1): 29.     CrossRef
    • HER2-targeted therapies beyond breast cancer — an update
      Jeesun Yoon, Do-Youn Oh
      Nature Reviews Clinical Oncology.2024; 21(9): 675.     CrossRef
    • Emerging Targeted Therapies for HER2-Positive Breast Cancer
      María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci
      Cancers.2023; 15(7): 1987.     CrossRef
    • Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
      Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Dapeng Dai, Yunfang Zhou, Qingjun Wu
      Thoracic Cancer.2023; 14(14): 1276.     CrossRef
    • Neratinib for HER2-positive breast cancer with an overlooked option
      Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang
      Molecular Medicine.2023;[Epub]     CrossRef
    • Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
      Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Kenichi Suda, Kazuko Sakai, Hidenori Sato, Tetsuya Mitsudomi
      JTO Clinical and Research Reports.2023; 4(9): 100554.     CrossRef
    • Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
      Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
      Cancer Research.2023; 83(18): 3145.     CrossRef
    • In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
      Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar
      Medicina.2023; 59(11): 1923.     CrossRef
    • Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
      María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo, Teresa Téllez
      Cancers.2023; 15(23): 5499.     CrossRef
    • Novel HER-2 Targeted Therapies in Breast Cancer
      Catarina Lopes Fernandes, Diogo J. Silva, Alexandra Mesquita
      Cancers.2023; 16(1): 87.     CrossRef
    • Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer
      Jiyun Lee, Yeon Hee Park
      Future Oncology.2022; 18(1): 7.     CrossRef
    • Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
      Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski
      Journal of Clinical Oncology.2022; 40(7): 710.     CrossRef
    • HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
      Xin Yu, Xianxiu Ji, Chunxia Su
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
      Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
      Cancer Cell.2022; 40(7): 754.     CrossRef
    • Tailoring antiHer2 treatment strategies in breast cancer and beyond
      Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu
      Current Problems in Cancer.2022; 46(5): 100892.     CrossRef
    • HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
      Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
      Biomarker Research.2022;[Epub]     CrossRef
    • Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
      Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
      Journal of Personalized Medicine.2022; 12(10): 1651.     CrossRef
    • An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study
      Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang
      Bioanalysis.2022; 14(17): 1165.     CrossRef
    • Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
      Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
      Critical Reviews in Oncology/Hematology.2021; 160: 103299.     CrossRef
    • Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
      Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou
      Pharmaceutical Biology.2021; 59(1): 455.     CrossRef
    • Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
      Lara Ulrich, Alicia FC Okines
      Breast Cancer: Targets and Therapy.2021; Volume 13: 361.     CrossRef
    • Current therapeutic options for gastric adenocarcinoma
      C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
      Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
    • The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
      Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu
      Lung Cancer.2021; 160: 136.     CrossRef
    • Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
      Chia-Jung Li, Yen-Dun Tony Tzeng, Yi-Han Chiu, Hung-Yu Lin, Ming-Feng Hou, Pei-Yi Chu
      Cancers.2021; 13(12): 2978.     CrossRef
    • Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
      Debasis Das, Jingbing Wang, Jian Hong
      ChemMedChem.2021; 16(16): 2459.     CrossRef
    • Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors
      Seyed-Omar Zaraei, Rawan M. Sbenati, Nour N. Alach, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Mahmoud K. Shehata, Mohammed S. Abdel-Maksoud, Chang-Hyun Oh, Mohammed I. El-Gamal
      European Journal of Medicinal Chemistry.2021; 224: 113674.     CrossRef
    • Breast Cancer Treatments: Updates and New Challenges
      Anna Burguin, Caroline Diorio, Francine Durocher
      Journal of Personalized Medicine.2021; 11(8): 808.     CrossRef
    • Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
      M. Riudavets, I. Sullivan, P. Abdayem, D. Planchard
      ESMO Open.2021; 6(5): 100260.     CrossRef
    • A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
      Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
      Cancer Medicine.2021; 10(20): 7012.     CrossRef
    • In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
      Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi
      Lung Cancer.2021; 162: 79.     CrossRef
    • HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
      Ioannis A. Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N. Syrigos
      Pharmaceuticals.2021; 14(12): 1300.     CrossRef
    • Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
      Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang
      Journal of Thoracic Oncology.2020; 15(6): 962.     CrossRef
    • Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
      Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu
      Pharmacology & Therapeutics.2020; 206: 107438.     CrossRef
    • Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
      Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
      Critical Reviews in Oncology/Hematology.2020; 148: 102906.     CrossRef
    • Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
      Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang
      The Oncologist.2020; 25(3): e545.     CrossRef
    • Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
      Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel
      Clinical Lung Cancer.2020; 21(5): 428.     CrossRef
    • HER2-positive advanced breast cancer treatment in 2020
      Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja
      Cancer Treatment Reviews.2020; 88: 102033.     CrossRef
    • New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
      Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves
      Cancers.2020; 12(6): 1573.     CrossRef
    • HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
      Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang
      Frontiers in Oncology.2020;[Epub]     CrossRef
    • Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
      Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
      Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
    • EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
      Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse
      Cancer Treatment Reviews.2020; 90: 102105.     CrossRef
    • Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
      Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni
      Critical Reviews in Oncology/Hematology.2020; 156: 103119.     CrossRef
    • Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
      Xue Yang, Dapeng Wu, Shengli Yuan
      Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
    • Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
      Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
      Cancers.2020; 12(11): 3249.     CrossRef
    • Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
      Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
      Gastrointestinal Disorders.2020; 3(1): 1.     CrossRef
    • Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
      Apurva Pandey, Adam M. Brufsky
      Clinical Breast Cancer.2019; 19(1): e7.     CrossRef
    • Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
      Debasis Das, Jian Hong
      European Journal of Medicinal Chemistry.2019; 170: 55.     CrossRef
    • Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
      Wei Jiang, Meiju Ji
      Seminars in Cancer Biology.2019; 59: 3.     CrossRef
    • A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
      Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang
      Gastric Cancer.2019; 22(6): 1206.     CrossRef
    • Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
      Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
      Cancers.2019; 11(6): 737.     CrossRef
    • Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi
      Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park
      International Journal of Cancer.2019; 145(6): 1669.     CrossRef
    • Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
      Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha
      The Oncologist.2019; 24(12): e1303.     CrossRef
    • Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
      Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi
      Lung Cancer.2018; 126: 72.     CrossRef
    • A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial
      Yeon Hee Park, Kyung‐Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee‐Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae‐Yong Kim, Gun Min Kim, In Hae Park, Sung‐Bae Kim, Se Hyun Kim, Hye Sook Han, Young‐Hyuck Im, Jin‐Hee Ahn, Jung‐Yong Kim, Jahoon Kang
      International Journal of Cancer.2018; 143(12): 3240.     CrossRef
    • EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
      Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
      Clinical Cancer Research.2018; 24(24): 6548.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
      Cancer Res Treat. 2018;50(3):835-842.   Published online August 29, 2017
      Close
    • XML DownloadXML Download
    Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Image
    Fig. 1. (A) Waterfall plot shows tumor size changes of target lesions in patients who received poziotinib once daily on a 14-day on and 7-day off schedule (n=46). (B) Waterfall plot shows tumor size changes of target lesions in patients treated with poziotinib once daily continuously (n=16). (C) Waterfall plot for non-small cell lung cancer (NSCLC) patients.
    Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Characteristic Intermittent dosing schedule (n=55) Continuous dosing schedule (n=20)
    Sex
     Male 31 (56) 13 (65)
     Female 24 (44) 7 (35)
    Age (yr) 55 (25-83) 55 (32-77)
    ECOG PS
     0 30 (55) 8 (40)
     1 22 (40) 12 (60)
     2 2 (4) 0
     3 1 (2) 0
    Cancer
     NSCLC 22 (40) 5 (25)
     Stomach 10 (18) 3 (15)
     Breast 8 (15) 2 (10)
     Colorectal 9 (16) 6 (30)
     Others 6 (11) 4 (20)
    Prior regimen
     1-2 9 (16) 3 (15)
     3 9 (16) 5 (25)
     ≥ 4 37 (67) 12 (60)
    TEAEs, preferred terms Intermittent dosing schedule (n=55)
    Continuous dosing schedule (n=20)
    Grade 1-4 ≥ Grade 3 Grade 1-4 ≥ Grade 3
    Diarrhea 48 (87) 8 (15) 20 (100) 3 (15)
    Rash 46 (84) 1 (2) 13 (65) -
    Stomatitis 40 (73) - 16 (80) 1 (5)
    Pruritus 33 (60) - 11 (55) 1 (5)
    Decreased appetite 20 (36) 1 (2) 11 (55) 2 (10)
    Acne 17 (31) - - -
    Dermatitis acneiform 2 (4) - 6 (30) 2 (10)
    Palmar-plantar erythrodysaesthesia syndrome 18 (33) - 3 (15) -
    Rhinorrhea 14 (26) - 6 (30) -
    Paronychia 13 (24) - 13 (65) -
    Mucosal inflammation 13 (24) 1 (2) 6 (30) -
    Nausea 11 (20) 1 (2) 4 (20) -
    Vomiting 10 (18) 1 (2) 4 (20) -
    Fatigue 8 (15) - 3 (15) -
    Skin exfoliation 8 (15) - - -
    Dry skin 6 (11) - 6 (30) 2 (10)
    Weight decreased 6 (11) - - -
    Dose (mg) Intermittent dosing schedule
    Continuous dosing schedule
    No. of patients No. of DLTs DLT details No. of patients No. of DLTs DLT details
    0.5 3 - - - - -
    1 3 - - - - -
    2 3 - - - - -
    4 3 - - - - -
    8 3 - - - - -
    12 6 1 Diarrhea 3 - -
    16 6 1 Diarrhea - - -
    18 - - - 6 1 Decreased appetite
    20 3 - - - - -
    24 6 1 Diarrhea 3 1 Diarrhea
    Drug compliance < 80%
    32 7 2 Diarrhea - - -
    24 Extension 12 5 3 Diarrhea, 1 nausea, 1 mucosal inflammation - - -
    Table 1. Patient characteristics

    Values are presented as number (%) or median (range). ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer.

    Table 2. Poziotinib-related TEAEs (≥ 10%)

    Values are presented as number (%). TEAEs, treatment-emergent adverse events.

    Table 3. DLTs in dose escalation and extension phases

    DLT, dose-limiting toxicity.


    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP